• +1-646-491-9876
    • +91-20-67278686

    Search

    Chemotherapy Induced Anemia - Pipeline Review, H1 2017

    Chemotherapy Induced Anemia - Pipeline Review, H1 2017

    • Report Code ID: RW0001709434
    • Category Pharmaceuticals
    • No. of Pages 59
    • Publication Month Mar-17
    • Publisher Name Global Markets Direct
    Chemotherapy Induced Anemia - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Anemia - Pipeline Review, H1 2017, provides an overview of the Chemotherapy Induced Anemia (Toxicology) pipeline landscape.

    Chemotherapy-induced anemia is a very common side effect of cancer treatment. Symptoms include severe fatigue, weakness, anxiety, lack of energy, shortness of breath, headaches, pale appearance, rapid heart rate or palpitations, chest pain dizziness, cognitive impairment, loss of sexual desire, inability to perform daily functions and/or depression associated with anemia. The predisposing factors include age, co-morbidities, time course of therapy.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Chemotherapy Induced Anemia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Anemia (Toxicology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Chemotherapy Induced Anemia (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Anemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 2, 3 and 6 respectively.

    Chemotherapy Induced Anemia (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Anemia (Toxicology) .
    - The pipeline guide reviews pipeline therapeutics for Chemotherapy Induced Anemia (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Chemotherapy Induced Anemia (Toxicology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Chemotherapy Induced Anemia (Toxicology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Chemotherapy Induced Anemia (Toxicology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Chemotherapy Induced Anemia (Toxicology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Chemotherapy Induced Anemia (Toxicology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Chemotherapy Induced Anemia - Overview
    Chemotherapy Induced Anemia - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Chemotherapy Induced Anemia - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Chemotherapy Induced Anemia - Companies Involved in Therapeutics Development
    3SBio Inc
    Chong Kun Dang Pharmaceutical Corp
    Dr. Reddy's Laboratories Ltd
    Galenica Ltd
    Novartis AG
    Panacea Biotec Ltd
    Pfizer Inc
    PharmaEssentia Corp
    PhytoHealth Corp
    Pieris Pharmaceuticals Inc
    SBI Pharmaceuticals Co Ltd
    Therapure Biopharma Inc
    Tolero Pharmaceuticals Inc
    Chemotherapy Induced Anemia - Drug Profiles
    (aminolevulinic acid hydrochloride + sodium ferrous citrate) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    darbepoetin alfa - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    darbepoetin alfa - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    darbepoetin alfa biosimilar - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    epoetin alfa - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    epoetin zeta - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ferric carboxymaltose - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pegylated erythropoietin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PHEP-01 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PRS-080 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SSS-06 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TBI-304H - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TP-0184 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TP-0413 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TXA-302 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Chemotherapy Induced Anemia - Dormant Projects
    Chemotherapy Induced Anemia - Discontinued Products
    Chemotherapy Induced Anemia - Product Development Milestones
    Featured News & Press Releases
    Mar 11, 2015: Therapure Innovations Receives FDA Approval to Proceed with a Phase 1 Clinical Trial of Its Novel Anemia Therapeutic TBI 304H
    Oct 30, 2012: SBI Pharmaceuticals Submits a Phase-1 Clinical Trial CTA to MHRA for a Drug to Treat Cancer Chemotherapy-induced Anemia
    Apr 24, 2012: SBI Pharmaceuticals Announces Obtainment of Marketing Authorization of Products Containing 5-ALA from The Kingdom of Bahrain Ministry of Health
    Oct 28, 2011: ALA Study Results Presented at the 49th Annual Meeting of Japan Society of Clinical Oncology
    Oct 21, 2011: ALA Study Results Presented at 39th Annual Meeting of Japanese Association for Acute Medicine
    Oct 05, 2011: ALA Study Results Presented at Japanese Cancer Association, 70th Annual Meeting
    Oct 03, 2011: ALA Study Results Presented at Japanese Society of Parasitology, 71st Meeting
    Mar 18, 2011: Announcement of publication of ALA research in International Immunopharmacology
    Sep 30, 2010: Safety study for subcutaneous epoetin alfa biosimilar Binocrit/Epoetin alfa Hexal/Abseamed suspended
    Aug 09, 2010: Dr Reddy's Launches Darbepoetin Alfa For Treatment Of Anemia In India
    Feb 22, 2010: Retacrit Received a Positive Opinion From the European Committee for Medicinal Products for Human Use (CHMP) for Subcutaneous (SC) use in Renal Anaemia
    Dec 01, 2008: International presentation of clinical safety and efficacy data for Binocrit, the world's first complex biosimilar
    Jan 07, 2008: Sandoz and Gambro form strategic alliance
    Dec 19, 2007: Hospira's Retacrit Receives Marketing Authorization in the EU
    Oct 18, 2007: Hospira's Biosimilar Epoetin Retacrit Receives Positive Opinion Recommending EU Approval
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Chemotherapy Induced Anemia, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Chemotherapy Induced Anemia - Pipeline by 3SBio Inc, H1 2017
    Chemotherapy Induced Anemia - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2017
    Chemotherapy Induced Anemia - Pipeline by Dr. Reddy's Laboratories Ltd, H1 2017
    Chemotherapy Induced Anemia - Pipeline by Galenica Ltd, H1 2017
    Chemotherapy Induced Anemia - Pipeline by Novartis AG, H1 2017
    Chemotherapy Induced Anemia - Pipeline by Panacea Biotec Ltd, H1 2017
    Chemotherapy Induced Anemia - Pipeline by Pfizer Inc, H1 2017
    Chemotherapy Induced Anemia - Pipeline by PharmaEssentia Corp, H1 2017
    Chemotherapy Induced Anemia - Pipeline by PhytoHealth Corp, H1 2017
    Chemotherapy Induced Anemia - Pipeline by Pieris Pharmaceuticals Inc, H1 2017
    Chemotherapy Induced Anemia - Pipeline by SBI Pharmaceuticals Co Ltd, H1 2017
    Chemotherapy Induced Anemia - Pipeline by Therapure Biopharma Inc, H1 2017
    Chemotherapy Induced Anemia - Pipeline by Tolero Pharmaceuticals Inc, H1 2017
    Chemotherapy Induced Anemia - Dormant Projects, H1 2017
    Chemotherapy Induced Anemia - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Chemotherapy Induced Anemia, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    3SBio Inc
    Chong Kun Dang Pharmaceutical Corp
    Dr. Reddy's Laboratories Ltd
    Galenica Ltd
    Novartis AG
    Panacea Biotec Ltd
    Pfizer Inc
    PharmaEssentia Corp
    PhytoHealth Corp
    Pieris Pharmaceuticals Inc
    SBI Pharmaceuticals Co Ltd
    Therapure Biopharma Inc
    Tolero Pharmaceuticals Inc

    Request for Sample

    Report Url http://www.reportsweb.com//chemotherapy-induced-anemia-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//chemotherapy-induced-anemia-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//chemotherapy-induced-anemia-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments